{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:21:31Z","timestamp":1787728891135,"version":"build-2784847793"},"reference-count":40,"publisher":"Impact Journals, LLC","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,7,26]]},"DOI":"10.18632\/oncotarget.10351","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T02:57:46Z","timestamp":1467341866000},"page":"48059-48069","source":"Crossref","is-referenced-by-count":21,"title":["The emergence of T790M mutation in <i>EGFR<\/i>-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M"],"prefix":"10.18632","volume":"7","author":[{"given":"Jeng-Sen","family":"Tseng","sequence":"first","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yi","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Chieh","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Hsuan","family":"Hsu","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan"},{"name":"Division of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Statistical Science, Academia Sinica, Taipei, Taiwan"},{"name":"College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"College of Life Science, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ren","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Institute of Molecular Biology, National Chung-Hsing University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Liang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Center of Genomic Medicine, National Taiwan University College of Medicine, Taipei, Taiwan"},{"name":"Department of Pathology and Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"Center for Optoelectronic Biomedicine, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan"},{"name":"Comprehensive Cancer Center, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(13)61502-0","article-title":"Management of non-small-cell lung cancer: recent developments","volume":"382","author":"Rabe","year":"2013","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(13)61715-8","article-title":"Genetics and biomarkers in personalisation of lung cancer treatment","volume":"382","author":"Karachaliou","year":"2013","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"e0120852","DOI":"10.1371\/journal.pone.0120852","article-title":"Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan","volume":"10","author":"Chen","year":"2015","journal-title":"PloS one"},{"key":"5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Yang","year":"2014","journal-title":"Journal of thoracic oncology"},{"key":"6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Au","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"key":"7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Yang","year":"2009","journal-title":"The New England journal of medicine"},{"key":"8","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/JTO.0b013e31822adaf7","article-title":"Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)","volume":"6","author":"Magill","year":"2011","journal-title":"Journal of thoracic oncology"},{"key":"9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Miller","year":"2010","journal-title":"Journal of clinical oncology"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1200\/EdBook_AM.2013.33.e272","article-title":"Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents","author":"Doebele","year":"2013","journal-title":"American Society of Clinical Oncology educational book"},{"key":"11","first-page":"75ra26","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Temel","year":"2011","journal-title":"Science translational medicine"},{"key":"12","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Riely","year":"2013","journal-title":"Clinical cancer research"},{"key":"13","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1002\/cncr.28364","article-title":"Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations","volume":"119","author":"Otsuka","year":"2013","journal-title":"Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Kim","year":"2015","journal-title":"The New England journal of medicine"},{"key":"15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-10-2277","article-title":"Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay","volume":"17","author":"Ladanyi","year":"2011","journal-title":"Clinical cancer research"},{"key":"16","first-page":"90ra59","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"de Stanchina","year":"2011","journal-title":"Science translational medicine"},{"key":"17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.lungcan.2014.03.011","article-title":"T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients","volume":"84","author":"Zhou","year":"2014","journal-title":"Lung cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","volume":"17","author":"Miller","year":"2011","journal-title":"Clinical cancer research"},{"key":"19","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1158\/1078-0432.CCR-10-2571","article-title":"New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer","volume":"17","author":"Pao","year":"2011","journal-title":"Clinical cancer research"},{"key":"20","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Riely","year":"2011","journal-title":"Clinical cancer research"},{"key":"21","doi-asserted-by":"crossref","first-page":"1000124","DOI":"10.4172\/2329-6917.1000124","article-title":"Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine","volume":"1","author":"Sabaawy","year":"2013","journal-title":"Journal of leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1158\/0008-5472.CAN-06-4625","article-title":"Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation","volume":"67","author":"Haber","year":"2007","journal-title":"Cancer research"},{"key":"23","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1158\/0008-5472.CAN-06-4293","article-title":"Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib","volume":"67","author":"Settleman","year":"2007","journal-title":"Cancer research"},{"key":"24","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1371\/journal.pone.0000810","article-title":"Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors","volume":"2","author":"Pao","year":"2007","journal-title":"PloS one"},{"key":"25","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/ng1671","article-title":"Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR","volume":"37","author":"Haber","year":"2005","journal-title":"Nature genetics"},{"key":"26","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"372","author":"Galasso","year":"2015","journal-title":"The New England journal of medicine"},{"key":"27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2016.01.019","article-title":"Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis","volume":"94","author":"Yang","year":"2016","journal-title":"Lung cancer"},{"key":"28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","article-title":"Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer","volume":"30","author":"Yang","year":"2012","journal-title":"Journal of clinical oncology"},{"key":"29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/annonc\/mdt573","article-title":"Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing","volume":"25","author":"Riely","year":"2014","journal-title":"Annals of oncology"},{"key":"30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Raoof","year":"2016","journal-title":"Nature medicine"},{"key":"31","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","article-title":"Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI","volume":"10","author":"Yatabe","year":"2015","journal-title":"Journal of thoracic oncology"},{"key":"32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2015.11.016","article-title":"Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer","volume":"91","author":"Mitsudomi","year":"2016","journal-title":"Lung cancer"},{"key":"33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/JTO.0000000000000443","article-title":"Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma","volume":"10","author":"Chang","year":"2015","journal-title":"Journal of thoracic oncology"},{"key":"34","doi-asserted-by":"crossref","first-page":"809835","DOI":"10.1155\/2015\/809835","article-title":"Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments","volume":"2015","author":"Jekunen","year":"2015","journal-title":"Journal of oncology"},{"key":"35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/cas.12847","article-title":"Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study","volume":"107","author":"Negoro","year":"2016","journal-title":"Cancer science"},{"key":"36","doi-asserted-by":"crossref","first-page":"20913","DOI":"10.1038\/srep20913","article-title":"Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance","volume":"6","author":"Chen","year":"2016","journal-title":"Scientific reports"},{"key":"37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/2159-8290.CD-15-0399","article-title":"Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor","volume":"5","author":"Raponi","year":"2015","journal-title":"Cancer discovery"},{"key":"38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2014.03.016","article-title":"Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients","volume":"85","author":"Smit","year":"2014","journal-title":"Lung cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1)","volume":"45","author":"Dodd","year":"2009","journal-title":"European journal of cancer"},{"key":"40","doi-asserted-by":"crossref","first-page":"e107160","DOI":"10.1371\/journal.pone.0107160","article-title":"Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma","volume":"9","author":"Wu","year":"2014","journal-title":"PloS one"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T22:50:54Z","timestamp":1589237454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":40,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2016,7,26]]}},"alternative-id":["10351","27384480"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10351","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}